What is the share price of Emmessar Biotech and Nutrition Ltd (EMMESSA) today?
The share price of EMMESSA as on 5th December 2025 is ₹29.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Emmessar Biotech and Nutrition Ltd (EMMESSA) share?
The past returns of Emmessar Biotech and Nutrition Ltd (EMMESSA) share are- Past 1 week: -9.87%
- Past 1 month: -9.19%
- Past 3 months: 9.53%
- Past 6 months: -10.89%
- Past 1 year: -35.73%
- Past 3 years: -8.32%
- Past 5 years: 2.71%
What are the peers or stocks similar to Emmessar Biotech and Nutrition Ltd (EMMESSA)?
The peers or stocks similar to Emmessar Biotech and Nutrition Ltd (EMMESSA) include:What is the market cap of Emmessar Biotech and Nutrition Ltd (EMMESSA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Emmessar Biotech and Nutrition Ltd (EMMESSA) is ₹14.59 Cr as of 5th December 2025.What is the 52 week high and low of Emmessar Biotech and Nutrition Ltd (EMMESSA) share?
The 52-week high of Emmessar Biotech and Nutrition Ltd (EMMESSA) is ₹47.96 and the 52-week low is ₹25.80.What is the PE and PB ratio of Emmessar Biotech and Nutrition Ltd (EMMESSA) stock?
The P/E (price-to-earnings) ratio of Emmessar Biotech and Nutrition Ltd (EMMESSA) is 47.06. The P/B (price-to-book) ratio is 1.89.Which sector does Emmessar Biotech and Nutrition Ltd (EMMESSA) belong to?
Emmessar Biotech and Nutrition Ltd (EMMESSA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Emmessar Biotech and Nutrition Ltd (EMMESSA) shares?
You can directly buy Emmessar Biotech and Nutrition Ltd (EMMESSA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Emmessar Biotech and Nutrition Ltd
EMMESSA Share Price
29.201.52% (-0.45)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
EMMESSA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
EMMESSA Performance & Key Metrics
EMMESSA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 60.79 | 1.89 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
EMMESSA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
EMMESSA Company Profile
Emmessar Biotech and Nutrition Ltd operates in the healthcare sector, manufacturing and trading a diverse range of products addressing various health concerns, including dermatology and muscular pains.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
EMMESSA Forecast
EMMESSA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
EMMESSA
EMMESSA
Income
Balance Sheet
Cash Flow
Annual Normal View
EMMESSA Income Statement
EMMESSA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3.59 | 2.52 | 1.93 | 4.87 | 8.46 | 2.28 | 2.77 | 2.55 | 2.62 | 2.49 | ||||||||||
Raw Materials | 0.97 | 0.51 | 0.55 | 2.24 | 2.64 | 0.13 | 0.45 | 0.17 | 0.20 | 1.63 | ||||||||||
| Power & Fuel Cost | 0.01 | 0.02 | 0.02 | 0.02 | 0.00 | 0.02 | 0.02 | 0.02 | 0.02 | |||||||||||
| Employee Cost | 0.38 | 0.41 | 0.58 | 0.58 | 0.64 | 0.77 | 0.84 | 0.96 | 0.93 | |||||||||||
| Selling & Administrative Expenses | 0.29 | 0.21 | 0.27 | 0.25 | 0.26 | 0.26 | 0.29 | 0.39 | 0.35 | |||||||||||
| Operating & Other expenses | 0.73 | 0.52 | 0.14 | 0.97 | 2.60 | 0.08 | 0.11 | 0.10 | 0.07 | |||||||||||
EBITDA | 1.21 | 0.85 | 0.37 | 0.81 | 2.32 | 1.02 | 1.06 | 0.91 | 1.05 | 0.86 | ||||||||||
| Depreciation/Amortization | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.10 | 0.09 | ||||||||||
| PBIT | 1.20 | 0.80 | 0.29 | 0.75 | 2.26 | 0.93 | 0.97 | 0.81 | 0.95 | 0.77 | ||||||||||
| Interest & Other Items | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | 1.19 | 0.80 | 0.29 | 0.75 | 2.26 | 0.93 | 0.97 | 0.81 | 0.95 | 0.77 | ||||||||||
| Taxes & Other Items | 0.00 | -0.12 | -0.24 | -0.02 | 0.81 | 0.45 | 0.46 | 0.06 | 0.64 | 0.53 | ||||||||||
| Net Income | 1.19 | 0.92 | 0.53 | 0.77 | 1.45 | 0.48 | 0.51 | 0.75 | 0.31 | 0.24 | ||||||||||
| EPS | 2.38 | 1.84 | 1.06 | 1.54 | 2.90 | 0.96 | 1.02 | 1.50 | 0.62 | 0.48 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EMMESSA Company Updates
EMMESSA Stock Peers
EMMESSA Past Performance & Peer Comparison
EMMESSA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Emmessar Biotech and Nutrition Ltd | 47.06 | 1.89 | — |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
EMMESSA Stock Price Comparison
Compare EMMESSA with any stock or ETFCompare EMMESSA with any stock or ETF
EMMESSA
EMMESSA Holdings
EMMESSA Shareholdings
EMMESSA Promoter Holdings Trend
EMMESSA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
EMMESSA Institutional Holdings Trend
EMMESSA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
EMMESSA Shareholding Pattern
EMMESSA Shareholding Pattern
EMMESSA Shareholding History
EMMESSA Shareholding History
Foreign Institutions
smallcases containing EMMESSA stock
smallcases containing EMMESSA stock
Looks like this stock is not in any smallcase yet.
EMMESSA Events
EMMESSA Events
EMMESSA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
EMMESSA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
EMMESSA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
EMMESSA has not given any dividends in last 5 years
EMMESSA Dividends
EMMESSA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeEMMESSA Stock News & Opinions
EMMESSA Stock News & Opinions
Articles & Videos
Earnings
Emmessar Biotech & Nutrition standalone net profit declines 60.71% in the September 2025 quarter
Net profit of Emmessar Biotech & Nutrition declined 60.71% to Rs 0.11 crore in the quarter ended September 2025 as against Rs 0.28 crore during the previous quarter ended September 2024. Sales declined 73.53% to Rs 0.09 crore in the quarter ended September 2025 as against Rs 0.34 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales0.090.34 -74 OPM %-411.11-23.53 - PBDT0.170.43 -60 PBT0.140.41 -66 NP0.110.28 -61 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Emmessar Biotech & Nutrition to convene board meeting
Emmessar Biotech & Nutrition will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Corporate
Emmessar Biotech & Nutrition to convene AGM
Emmessar Biotech & Nutrition announced that the 33th Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Emmessar Biotech & Nutrition standalone net profit rises 88.89% in the June 2025 quarter
Net profit of Emmessar Biotech & Nutrition rose 88.89% to Rs 0.17 crore in the quarter ended June 2025 as against Rs 0.09 crore during the previous quarter ended June 2024. Sales rose 12.50% to Rs 0.09 crore in the quarter ended June 2025 as against Rs 0.08 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales0.090.08 13 OPM %-311.11-350.00 - PBDT0.250.18 39 PBT0.230.16 44 NP0.170.09 89 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Emmessar Biotech & Nutrition declare Quarterly Result
Emmessar Biotech & Nutrition will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Emmessar Biotech & Nutrition reports standalone net loss of Rs 0.07 crore in the March 2025 quarter
Net loss of Emmessar Biotech & Nutrition reported to Rs 0.07 crore in the quarter ended March 2025 as against net profit of Rs 0.27 crore during the previous quarter ended March 2024. Sales rose 25.00% to Rs 0.10 crore in the quarter ended March 2025 as against Rs 0.08 crore during the previous quarter ended March 2024. For the full year,net profit declined 50.77% to Rs 0.32 crore in the year ended March 2025 as against Rs 0.65 crore during the previous year ended March 2024. Sales rose 8.93% to Rs 0.61 crore in the year ended March 2025 as against Rs 0.56 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales0.100.08 25 0.610.56 9 OPM %-330.00-487.50 --155.74-192.86 - PBDT0.280.09 211 1.060.91 16 PBT0.260.07 271 0.960.81 19 NP-0.070.27 PL 0.320.65 -51 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Emmessar Biotech & Nutrition to hold board meeting
Emmessar Biotech & Nutrition will hold a meeting of the Board of Directors of the Company on 24 April 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Emmessar Biotech & Nutrition standalone net profit declines 84.62% in the December 2024 quarter
Net profit of Emmessar Biotech & Nutrition declined 84.62% to Rs 0.02 crore in the quarter ended December 2024 as against Rs 0.13 crore during the previous quarter ended December 2023. Sales declined 69.70% to Rs 0.10 crore in the quarter ended December 2024 as against Rs 0.33 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales0.100.33 -70 OPM %-280.00-63.64 - PBDT0.150.32 -53 PBT0.130.30 -57 NP0.020.13 -85 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Emmessar Biotech & Nutrition announces board meeting date
Emmessar Biotech & Nutrition will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Earnings
Emmessar Biotech & Nutrition standalone net profit rises 40.00% in the September 2024 quarter
Net profit of Emmessar Biotech & Nutrition rose 40.00% to Rs 0.28 crore in the quarter ended September 2024 as against Rs 0.20 crore during the previous quarter ended September 2023. Sales rose 325.00% to Rs 0.34 crore in the quarter ended September 2024 as against Rs 0.08 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales0.340.08 325 OPM %-23.53-275.00 - PBDT0.430.31 39 PBT0.410.29 41 NP0.280.20 40 Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -11.66%, vs industry avg of 10.04%
Over the last 5 years, market share stayed at 0%
Over the last 5 years, net income has grown at a yearly rate of -16.64%, vs industry avg of 20.02%